Alpha-GPC (L-alpha-glycerylphosphorylcholine)

Reviewed by the HeyPsych Medical Review Board

Board-certified psychiatrists and mental health professionals

Published August 17, 2025•Updated February 20, 2026•Reviewed February 20, 2026

Indications

Primary Indications

Investigated in Alzheimer’s disease and dementia for memory and cognitive supportPost-stroke cognitive rehabilitation (studies in Europe)Nootropic use for memory, focus, and learning enhancementAthletic performance (growth hormone release, anecdotal)

Mechanism

Alpha-GPC provides choline, which is a precursor to acetylcholine, a neurotransmitter critical for memory, learning, and attention. It also supports phospholipid synthesis in neuronal membranes, contributing to neuroprotection. Some evidence suggests it may increase growth hormone secretion, which may support exercise recovery.

Dosing

Adult Dosing

usual range: 300–600 mg once or twice daily

nootropic use: 300–600 mg/day

cognitive decline: 1,200 mg/day in divided doses (used in clinical studies in Europe)

Dosage Forms

Capsules (300–600 mg)
Powder

Onset Duration

Acute nootropic effects (focus, attention) may be noticed within hours. Cognitive benefits in dementia trials required weeks to months of consistent use.

Adverse Effects

Common Side Effects

• headache

• GI upset

• insomnia

• nervousness

⚠️ Serious Side Effects

rare cases of hypotension or dizziness at high doses

Warnings

Critical Safety Information

→Use with caution in patients with mood or anxiety disorders, as cholinergic effects can sometimes worsen symptoms.
→High doses may cause insomnia or restlessness.

Interactions

With: Anticholinergic medications

Risk: Reduced efficacy of both agents

Action: Avoid or monitor closely

With: Cholinesterase inhibitors

Risk: Additive cholinergic effects

Action: Monitor for excessive cholinergic symptoms

With: Stimulants

Risk: Possible additive insomnia or restlessness

Action: Monitor

Monitoring

Cognitive changes
Sleep quality
GI tolerance

Special Populations

👶Pregnancy

Insufficient data; avoid use unless supervised

🤱Breastfeeding

Insufficient safety data; avoid use

👧Children & Adolescents (Under 18)

Not well studied; avoid use

👴Older Adults (65+)

Used in dementia studies; appears safe at studied doses

Tapering

No tapering required; can discontinue without withdrawal.

Clinical Notes

Widely available as a nootropic supplement but quality and purity vary.
Evidence is strongest for Alzheimer’s and stroke recovery in European studies, but remains limited and inconsistent.
Often stacked with other nootropics or racetams for synergistic effects in cognitive enhancement communities.

This treatment information is for educational purposes only. Treatment decisions should be made in consultation with qualified healthcare professionals based on individual circumstances, symptoms, and medical history. Do not attempt treatment without professional guidance.

Interested in this treatment?

This information is for educational purposes. Always consult with a qualified healthcare provider before starting any new treatment.

Locate Psychiatrists